02.18.20

LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery System

Source: LumiThera

LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). 

“Recent research in our labs in both preclinical and clinical areas have indicated potential in treating diabetic edema with PBM,” Janis Eells, PhD, Professor, University of Wisconsin-Milwaukee, said in a company news release. “Our work shows that early PBM benefits in reducing the detrimental effects of high glucose on retinal cells and early human data is now starting to show benefits in the clinical setting.”

DR is the leading cause of blindness in the world. The International Diabetes Foundation 2019 Fact Sheet estimated that globally 463 million people have diabetes now, and future estimates suggest that this number will increase to 578 million by the year 2030.

“We have been working with Dr. Eells and the University of Wisconsin-Milwaukee on our dry AMD research and the work in DR and diabetic macular edema (DME) is a logical extension of our PBM platform,” Clark E. Tedford, PhD, President and CEO of LumiThera, said in the news release. “The results from Dr. Eell’s lab point to the multiple cellular benefits of treating the disease early and PBM would be an alternative approach for treatment of early disease.”

LumiThera was granted a CE mark to commercialize the Valeda System in European Union for the treatment of ocular diseases including dry AMD. The company previously announced that the National Institutes of Health and division of the National Eye Institute have provided a $2.5M grant to support the LIGHTSITE II multicenter clinical trial to lead to U.S. approval for dry AMD. The company is enrolling two multicenter trials, one in European Union and one in the US for dry AMD. The entry into DME provides a second major ocular disease platform for the Valeda system.

“We are excited to be involved in the development of Valeda for both non-neovascular (dry) AMD and DME. We are currently enrolling patients in the LIGHTSITE III study and believe that PBM could be an even bigger platform for DME,” said Quan Dong Nguyen, MD, M.Sc. and Diana V. Do, MD, Professors of Ophthalmology at the Byers Eye Institute, Stanford University. “DME is the leading cause of functional vision loss among working adults worldwide. Treatments with intravitreal injections of pharmacologic agents are effective but can be costly and invasive. PBM could provide a significant improvement to the current practices with its non-invasive approach.”

“I am continually impressed with the scientific foundation that LumiThera is building for PBM with collaborations in both preclinical and clinical research,” stated David Boyer, MD, Retina-Vitreous Associates Medical Group. “The benefits for PBM on multiple critical cellular pathways involved in the disease etiology in preclinical work is now being evaluated in the clinical setting and could change the way we address chronic disease that leads to blindness.”

 

Related Content